Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Dec 8;15:899–912. doi: 10.2147/BCTT.S434973

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 Hu et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Effects of TQB3616, abemaciclib, fulvestrant, trastuzumab and their combination on the proliferation of HR-positive breast cancer cell lines. (A–D) The proliferation rates of T47D, MCF-7, BT474, and MDA-MB-361 cell lines were measured by CCK-8 assay after treatment for 72 hours with various concentrations of TQB3616, abemaciclib, and fulvestrant. (E and F) T47D and MCF-7 cells were treated with different concentrations of TQB3616 or abemaciclib in combination with fulvestrant for 72 hours. (G and H) TQB3616 or abemaciclib was combined with trastuzumab to inhibit BT474 and MDA-MB-361 cells for 72 hours.